Drugmakers Zydus Cadila said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients’ company is going to start phase 3 trials with PegiHep soon. The trials will start in December in the start it will be conducted on 250 patients across 20-25centres in India.The company is going to start further trials a similar phase 2 in Mexico and the US Food and Drug Administration (USFDA) to start the Investigational New Drug(IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in US.
Zydus Cadila to start Phase -3 trials soon
previous post